RELX PLC (R1EL34)
B3 Stock Exchange · Brazil · prices in BRL · close of 26 Oct 2026
Key indicators
| Last close | BRL 53.90 |
|---|---|
| 52-week range | 35.87 – 67.00 |
| Return, 1 month / 3 months | +29.9% / +31.0% |
| Return, 1 year / 3 years | −10.1% / +31.9% |
| Trend | Uptrend |
| RSI (14) | 96 |
| Volatility (1 year) | 73.6% |
| Worst drawdown (1 year) | -46.0% |
| Average daily value traded | 0.00M BRL |
| Dividend yield | 15.8% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
RELX PLC is an information and analytics company based in London. It provides scientific, technical and medical research information and tools to researchers and healthcare professionals, legal and business information and risk analytics to law firms, insurers and corporations, and industry exhibitions and trade shows to business audiences. Its products include online research platforms, data services and decision tools used by professionals in many countries.
RELX PLC is represented on the B3 Stock Exchange in Brazil by a Brazilian depositary receipt (BDR) under the code R1EL34, with its price quoted in Brazilian reais (BRL). Our dividend records, which start in 2019, show payments in 6 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
RELX PLC (R1EL34) trades on the B3 Stock Exchange in Brazil. It last closed at BRL 53.90 on 26 October 2026.
Its price-based Market X-Ray is 44 out of 100 (a weak price profile), ranking 909 of 1,455 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 10.1% and over the last three months it rose 31.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on B3 Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 61 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 25.0% | ||
| From 52-week high | -19.6% | ||
| Momentum | 63 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 31.0% | ||
| 6-month return | 21.8% | ||
| 12-month return, skipping the last month | -30.7% | ||
| Stability (higher is calmer) | 20 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 73.6% | ||
| Worst drawdown, 1 year (smaller is calmer) | -46.0% | ||
| Liquidity | 11 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.00M BRL | ||
| Zero-volume days | 91.7% | ||
| Income | 61 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 15.8% | ||
| Years with dividends | 5 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +9.4% |
|---|---|
| 1 month | +29.9% |
| 3 months | +31.0% |
| 6 months | +21.8% |
| 1 year | −10.1% |
| 3 years | +31.9% |
| 5 years | +41.3% |
Signals
| 50-day / 200-day average | 42.56 / 43.13 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.78 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 6 Aug 2026 | GBP 0.3635 |
| 7 May 2026 | GBP 0.8234 |
| 7 Aug 2025 | GBP 0.3496 |
| 8 May 2025 | GBP 0.8307 |
| 1 Aug 2024 | GBP 0.3372 |
| 2 May 2024 | GBP 0.6541 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on B3 Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.